FHA
TRVI icon

First Horizon Advisors’s Trevi Therapeutics TRVI Stock Holding History

First Horizon Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$2.73K Buy
+500
New +$3.11K ﹤0.01% 1975

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

First Horizon Advisors's TRVI Position: Q2 2025 in Review

First Horizon Advisors opened a new position in Trevi Therapeutics (TRVI) in Q2 2025: 500 shares worth $2.73K. The stake represents ﹤0.01% of the portfolio and ranks #1975 among its holdings.

153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • First Horizon Advisors held 500 shares of Trevi Therapeutics worth $2.73K as of Q2 2025.
  • Trevi Therapeutics was a new First Horizon Advisors position in Q2 2025.
  • Trevi Therapeutics made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1975 holding.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.